General informationNotification NumberB/ES/09/11Member State to which the notification was sentSpainDate of acknowledgement from the Member State Competent Authority23/01/2009Title of the ProjectNotification according to Directive 2001/18/EC, Part B, for the deliberate release of genetically modified 1507 x 59122 maize (DAS-Ø15Ø7-1×DAS-59122-7) to select inbred lines and obtain varieties.Proposed period of release:01/04/2009 to 31/12/2009Name of the Institute(s) or Company(ies)Monsanto Europe, S.A., represented by Monsanto Agricultura España, S.L., ;
3. Is the same GMPt release planned elsewhere in the Community?NoHas the same GMPt been notified elsewhere by the same notifier?NoGenetically modified plantComplete name of the recipient or parental plant(s)
2. Description of the traits and characteristics which have been introduced or modified, including marker genes and previous modifications:1507 x 59122 maize is the result of the traditional breeding between progeny of two genetically modified maize: 1507 maize and 59122 maize. 1507 maize has been genetically modified to express the Cry1F and PAT proteins while, 59122 maize has been genetically transformed to express the Cry34Ab1, Cry35Ab1 and PAT proteins. Consequently, 1507 x 59122 maize expresses the Cry1F, Cry34Ab1, Cry35Ab1 and PAT proteins, conferring protection against certain Lepidopteran and Coleopteran insect pests along with tolerance to glufosinate ammonium herbicide (used as selectable marker).Genetic modification3. Type of genetic modification:Insertion; In case of insertion of genetic material, give the source and intended function of each constituent fragment of the region to be inserted:Traditional breeding techniques were used in the production of 1507 x 59122, that has inherited from:
|Common Name||Family Name||Genus||Species||Subspecies||Cultivar/breeding line|
- The cry1F gene from Bacillus thuringiensis strain aizawai, confers protection against certain lepidopteran insect pests, driven by UbiZM promoter and the ORF25 from Agrobacterium tumefaciens.
- The pat gene from Streptomyces viridochromogenes confers tolerance to glufosinate ammonium herbicide, driven by CaMV35S promoter and terminator, from cauliflower mosaic virus.
- The cry34Ab1 gene from Bacillus thuringiensis strain PS149B1, confers protection against certain Coleopteran insect pests, driven by UBIZM promoter, the PINII terminator from Solanum tuberosum.
- The cry35Ab1 gene from Bacillus thuringiensis strain PS149B1, confers protection against certain Coleopteran insect pests, driven by the Peroxidase promoter from Triticum aestivum, the PINII terminator from Solanum tuberosum. - The pat gene from Streptomyces viridochromogenes confers tolerance to glufosinate ammonium herbicide, driven by CaMV35S promoter and terminator, from cauliflower mosaic virus.6. Brief description of the method used for the genetic modification:No new genetic modification has been implemented in the production of 1507 x 59122 maize, produced through a traditional breeding cross between 1507 maize and 59122 maize. While 1507 maize was obtained by insertion of a linear DNA fragment (insert PHI8999A) using the particle acceleration method, the 59122 maize was genetically modified using Agrobacterium-mediated transformation on the maize line Hi II, using binary vector PHP17662.7. If the recipient or parental plant is a forest tree species, describe ways and extent of dissemination and specific factors affecting dissemination:Not relevant.Experimental Release1. Purpose of the release:The purpose of the release is to characterize inbred maize lines and increase the best ones, and to obtain hybrids varieties containing 1507 × 59122 (DAS-Ø15Ø7-1×DAS-59122-7) genetic modification.2. Geographical location of the site:Milagro (Navarra)3. Size of the site (m2):The total surface occupied by 1507 x 59122 maize will be less than:
- Milagro (Navarra): 1.000 m²4. Relevant data regarding previous releases carried out with the same GM-plant, if any, specifically related to the potential environmental and human health impacts from the release:Field trials have already been conducted in South America, North America and Europe. 1507 x 59122 maize plants were indistinguishable from the non GM maize plants, except for their protection against certain Lepidopteran and Coleopteran insect pests and tolerance to glufosinate ammonium herbicide.Environmental Impact and Risk ManagementSummary of the potential environmental impact from the release of the GMPts:No maize sexual compatible species have been found in Spain. Additionally, the field trials will be isolated from any other maize field by at least 200 m. Maize has a long history of safe use and been extensively domesticated by humans. The genes inherited by 1507 x 59122 maize: cry1F, cry34/35Ab1 and pat have a very specific mode of action, the cry genes conferring protection to some Lepidopteran and Coleopteran insect pests, and the latter conferring tolerance to the ammonium glufosinate herbicide. With the adoption of this technology the insecticide will be localized within the transgenic plants, reducing the environmental impact to surrounding areas and the farmers will reduce fuel costs and soil compaction through a substantial reduction in the numbers of applications required to control insect pests.Brief description of any measures taken for the management of risks:The environmental risk assessment has indicated that the environmental risk of this maize is negligible. Therefore, strategies for risk management for 1507 x 59122 maize would be the same as for traditional maize.
In addition to the scheduled observations of phenotypic and agronomic parameters that form the basis of the planned research, the trial site will be checked regularly during the period of the deliberate release for potentially occurring, direct or indirect, adverse environmental effects. This will be done by visual inspection of the status of the 1507 x 59122 crop and that of its receiving environment. In case of any adverse environmental effects linked to the deliberate release of 1507 x 59122, observed during the period of release, these will be reported immediately to the Competent Authority.
The spatial isolation distance (200 m) from other maize crops and the four rows of non transgenic maize surrounding the trials will prevent the risk of hybridization with other maize plants.
Seeds will be transported in sealed and labeled bags, and their management for setting the trial will be done by qualified staff, informed about preventive measures to avoid any spill. The equipments, especially the experimental drill and combine, will be cleaned on the experimental site, thus preventing seed dissemination.
Plant products from trials will be only used for studies intended by this notification and will be destroyed at their end. After completion of harvest, the stalks will be chopped and then incorporated into the soil. Harvested grain not used in further analysis or studies will be destroyed by burying, grinding to no viable fractions, incineration or authorized dump.
Although regrowth in the rotation crops is unlikely because of poor winter survival, the site will be sown either with a crop different from maize or with experimental maize that will be destroyed and not used in any commercial, industrial or food application. Volunteer plants will be controlled by mechanical destruction or other non-selective herbicides.
At the end of the field-testing campaign, a report will be made available by the notifier to the Competent Authority. This report will detail any unexpected adverse environmental effects that were observed during the general surveillance, if any, and further actions elicited as an effect of these findings, if applicable.Summary of foreseen field trial studies focused to gain new data on environmental and human health impact from the release:Not applicable. However, if any unanticipated adverse effects on human health or the environment would be observed, it will be reported immediately to the Competent Authority.Final reportEuropean Commission administrative informationConsent given by the Member State Competent Authority:Yes01/06/2009 00:00:00Remarks:The competent authority for give the consent of these field trials is the Autonomous Community of Navarra.